The first of several expected vaccine options for preventing
respiratory syncytial virus, or RSV, in older adults has been approved by
the FDA.The shot, called Arexvy, is made by the British pharmaceutical company GSK
and will be available by this fall. The company called it “the first RSV
vaccine for older adults to be approved anywhere in the world,” after the
FDA’s approval on Wednesday.
respiratory syncytial virus, or RSV, in older adults has been approved by
the FDA.The shot, called Arexvy, is made by the British pharmaceutical company GSK
and will be available by this fall. The company called it “the first RSV
vaccine for older adults to be approved anywhere in the world,” after the
FDA’s approval on Wednesday.
Arexvy is approved for people ages 60 and older, and trials showed it
reduced the risk of life-threatening complications from RSV, such as
pneumonia and bronchitis, by as much as 94%
